NeuroPace, Inc. (NPCE) Stock Price & Analysis
NeuroPace, Inc. (NPCE) closed at USD 12.93 on Wednesday, October 28, 2026, down 0.69% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 13.02; the Oct 28, 2026 session ranged USD 12.75–13.33 on volume of 189,504 shares. Market capitalization is $443.81M, with a 52-week range of USD 9.22–19.6 (NGM). Source: Nexqual, retrieved October 29, 2026 at 06:05 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NPCE.md
Key facts (NPCE)
- Last four reported quarters (through Jun 30, 2026): revenue $98.8M, net income -$19.1M (-19.3% margin), free cash flow -$11.6M (SEC filings).
- Analysts: Buy (mean 1.90 on a 1–5 scale) (10 analysts), mean target USD 20 (range 18–22).
- Total return with dividends: 1Y +27.6% vs S&P 500 +13.6%; 5Y -14.7% vs S&P 500 +79.8%.
- Next earnings: 2026-11-03, EPS estimate USD -0.09, revenue estimate $27.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NPCE)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $45.2M | $45.5M | $65.4M | $79.9M | $100.0M | $98.8M |
| Gross profit | $33.4M | $32.5M | $48.1M | $59.1M | $77.2M | — |
| Operating income | -$23.7M | -$40.8M | -$27.2M | -$21.7M | -$16.3M | -$15.1M |
| Net income | -$36.1M | -$47.1M | -$33.0M | -$27.1M | -$21.5M | -$19.1M |
| EPS (diluted) | -$2.17 | -$1.91 | -$1.27 | -$0.93 | -$0.66 | — |
| Free cash flow | -$25.0M | -$37.5M | -$19.9M | -$18.3M | -$11.3M | -$11.6M |
| Gross margin | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% | — |
| Operating margin | -52.5% | -89.6% | -41.5% | -27.1% | -16.3% | -15.3% |
| Net margin | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% | -19.3% |
| Revenue growth | +9.8% | +0.7% | +43.7% | +22.1% | +25.1% | — |
| Cash + short-term investments | $116M | $77.4M | $66.5M | $52.8M | $61.1M | — |
| Total debt | $49.8M | $52.9M | $57.0M | $59.5M | $58.9M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NPCE)
P/S 4.5x · EV/Sales 4.6x · P/B 37.4x · FCF yield -2.62% · Earnings yield -4.31% · Buyback yield (TTM) 0.00% · Net debt $7.3M · EV $451M
Analysts (NPCE)
Consensus Buy (mean 1.90 on a 1–5 scale), 10 analysts; mean target USD 20 (low 18, high 22).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-18 | Keybanc | Initiated | Overweight | $18 |
| 2026-07-29 | HC Wainwright & Co. | Reiterated | Buy | $20 |
| 2026-07-23 | Mizuho | Initiated | Outperform | $22 |
Total return (dividends reinvested) (NPCE)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +27.6% | -14.7% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +27.8% | -3.1% |
| Volatility (annualized) | 59.4% | 84.0% |
| Max drawdown | -36.5% (May 2026→Oct 2026) | -92.2% (Nov 2021→Dec 2022) |
NPCE earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.18 | −$0.19 | Beat +5.3% | — |
| — | Quarter ended Dec 31, 2025 | −$0.08 | −$0.15 | Beat +46.7% | — |
| — | Quarter ended Sep 30, 2025 | −$0.11 | −$0.19 | Beat +42.1% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
NPCE recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 4, 2026 | Schedule 13G/A | First Light Asset Management, LLC, Mathew P. Arens: 12.3% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | Schedule 13G/A | OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC: 4.4% of shares, passive 5%+ holder (amended) |
| Aug 11, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 11, 2026 | 8-K | Quarterly results |
| Jul 28, 2026 | 8-K | Regulation FD disclosure |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
NPCE suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Micro Systems Technologies Management | “For example, Micro Systems Technologies Management AG and Greatbatch Ltd are single source suppliers of key components of our products, including printed circuit assemblies and batteries.” |
| Partner | Rapport Therapeutics, Inc. (RAPP) | “In November 2023, we entered into a collaboration agreement with Rapport Therapeutics, Inc., or Rapport, a clinical-stage biotechnology company, to leverage our RNS System's unique biomarker monitoring and data analysis capabilities.” |
| Partner | Medtronic plc (MDT) | “On July 27, 2005, we entered into a cross-license agreement, or the Cross-License, with Medtronic, Inc., or Medtronic, directed to patent families in a field of use that is generally aligned with our business interests, including direct electrical stimulation or monitoring of the brain via electrodes attached to or implanted in the head for the treatment or diagnosis of epilepsy and other disorders, or the Field.” |
| Partner | Leerink Partners | “In November 2022, we entered into a Sales Agreement with Leerink Partners LLC, or Leerink, to sell shares of our common stock, from time to time, through an at-the-market, or ATM, equity offering program under which Leerink acted as our sales agent and pursuant to which we could sell common stock for aggregate gross proceeds of up to $50.0 million.” |
Quoted from the company's 10-K filed Mar 3, 2026.
Companies that name NPCE in their SEC reports
| Relationship to NPCE | Company | Filing | Sentence |
|---|---|---|---|
| customer | ClearPoint Neuro, Inc. (CLPT) | 10-K Mar 17, 2026 | “The only commercially available RNS system on the market is manufactured by NeuroPace.” |
| partner | Rapport Therapeutics, Inc. (RAPP) | 10-K Mar 10, 2026 | “In November 2023, we established a collaboration with NeuroPace to leverage the RNS system's data to track responses of patients receiving RAP-219 in our Phase 2a proof-of-concept trial.” |
NPCE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.09 | $-0.10 | +$0.02 | $27.2M | 8 |
| Next quarter (ends Dec 2026) | $-0.07 | $-0.08 | +$0.01 | $28.4M | 8 |
| Current fiscal year (ends Dec 2026) | $-0.43 | $-0.54 | +$0.11 | $100.3M | 9 |
| Next fiscal year (ends Dec 2027) | $-0.22 | $-0.29 | +$0.08 | $122.5M | 9 |
Key Statistics (as of October 29, 2026 at 06:05 UTC)
| Price | USD 12.93 |
|---|---|
| Change | ▼ 0.69% (down) |
| Previous Close | USD 13.02 |
| Open | USD 12.96 |
| Day Range | USD 12.75 – 13.33 |
| 52-Week Range | USD 9.22 – 19.6 |
| Volume | 189,504 shares |
| Market Cap | $443.81M |
| Exchange | NGM |
Technical Analysis (NPCE)
Nexqual's technical model rates NPCE "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 06:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.92 (neutral) |
| vs SMA50 | Below (USD 13.75) |
| MACD | -0.22 (negative) |
Analyst Ratings (NPCE)
Wall Street analysts rate NPCE "Buy" based on 10 analysts, with a mean price target of USD 20 (range USD 18–22), per Nexqual as of October 29, 2026 at 06:05 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 20 |
| High Target | USD 22 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (NPCE)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.09 |
| Revenue Estimate | $27.16M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.18 vs est -0.19 ▲ beat |
| 2025-12-31 | USD -0.08 vs est -0.15 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.19 ▲ beat |
Source: Nexqual, October 29, 2026 at 06:05 UTC.
Financials & Fundamentals (NPCE)
| Total Revenue | $106.99M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +17.10% |
| Gross Margin | +77.38% |
| Operating Margin | -22.53% |
| Profit Margin | -17.86% |
| ROE | -103.27% |
| Debt / Equity | 5.88 |
| Current Ratio | 4.94 |
| Total Cash | $51.70M |
| Total Debt | $69.93M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$11.61M (-11.7% of revenue) |
Source: Nexqual, October 29, 2026 at 06:05 UTC.
Financial Health Score (NPCE)
Nexqual rates NeuroPace, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 06:05 UTC.
| Growth | Strong — Revenue +25% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 80%, operating -15% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Weak — $52M cash and investments vs $59M debt (Jun 2026, SEC) |
| Cash Flow | Weak — FCF negative: -$12M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -161%, ROA -19.7% (last 4 quarters, SEC) |
Ownership (NPCE)
| Insider Ownership | +4.47% |
|---|---|
| Institutional Ownership | +97.31% |
| Shares Outstanding | 34.32M |
| Float | 25.57M |
| Short % of Float | +2.97% |
Source: Nexqual, October 29, 2026 at 06:05 UTC.
Leadership (NPCE)
NeuroPace, Inc. is led by Joel D. Becker, CEO, President & Director, per Nexqual as of October 29, 2026 at 06:05 UTC.
| CEO, President & Director | Joel D. Becker |
|---|---|
| Chief Financial Officer | Patrick F. Williams |
| Vice President of Marketing | Katie Keller |
| Senior Vice President of Sales | Chris Reese |
| Vice President of Human Resources | Amy Treadwell |
Major Backers & Investors (NPCE)
Notable institutional backers of NeuroPace, Inc. include Polar Capital Holdings PLC, Soleus Capital Management, L.P., First Light Asset Management, LLC, according to Nexqual as of October 29, 2026 at 06:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Polar Capital Holdings PLC | 9.61% |
| Soleus Capital Management, L.P. | 8.48% |
| First Light Asset Management, LLC | 8.34% |
| Morgan Stanley | 7.73% |
| Orbimed Advisors LLC. | 4.39% |
| Driehaus Capital Management, LLC | 4.22% |
| Armistice Capital, LLC | 2.02% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.22% |
| Vanguard Group | 3.57% |
| Deutsche Bank AG | 2.74% |
Source: Nexqual, October 29, 2026 at 06:05 UTC.
From NeuroPace, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Our paradigm-shifting RNS System is currently indicated in the United States for use in adult epilepsy patients, meaning patients who are 18 years of age or older, with drug-resistant focal epilepsy, which we believe represents an approximately $27 billion total addressable market.
- We do not believe we will need to modify our RNS System for potential use in generalized epilepsy or in patients under the age of 18; however, we will need to complete clinical studies and obtain FDA approval prior to marketing the RNS System for these indications.
- We will need to conduct additional studies to determine if any modifications to the RNS System are necessary to address these other brain disorders and to obtain FDA approval for any new indications.
- In 2023, we received FDA approval of a Premarket Approval Supplement, or PMA-S, which updated the qualification criteria for centers and clinicians that may prescribe and implant the RNS System.
Partnerships
- In 2025, we began a collaboration with Medical Device Innovation Consortium's, National Evaluation System for health Technology, or NEST, and the FDA to pursue the use of real-world data to support expanded labeling for pediatric patients.
- In November 2023, we entered into a collaboration agreement with Rapport Therapeutics, Inc., or Rapport, a clinical-stage biotechnology company, to leverage our RNS System's unique biomarker monitoring and data analysis capabilities.
Legal & Regulatory Risks (Item 1A, quoted)
- Our products are subject to extensive regulation by the FDA in the United States. Before a new medical device or a new intended use for an existing medical device can be marketed in the United States, we must first submit and receive either 510(k) clearance pursuant to Section 510(k) of the Food, Drug and Cosmetic Act, or the FDCA, or approval of a PMA application or PMA-S from the FDA, unless an exemption applies.
- Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our business, financial condition and results of operations.
- Regulatory compliance is expensive, complex and uncertain, and a failure to comply could lead to enforcement actions against us and other negative consequences for our business.
- Our operations are subject to pervasive and continuing FDA regulatory requirements, and failure to comply with these requirements could harm our growth potential, and our business, financial condition and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATEC | Alphatec Holdings, Inc. | USD 11.45 | ▲ 5.34% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| ALMR | Alamar Biosciences, Inc. | USD 34.3 | ▲ 7.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:05 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt